Novartis’ third quarter earnings call on October 18 yielded some important takeaways, as outlined in this essential article from Scrip. With a discussion of their expansion into radiopharmceuticals via their acquisition of Endocyte accounting for a portion of the call, Novartis executives also spent time sharing commercial updates for their new drug launches, including Kymriah (tisagenlecleucel), Kisqali (ribociclib), Cosentyx (secukinumab), and Aimovig (erenumab). In addition, Novartis representatives discussed the latest regulatory developments concerning its late-state pipeline candidates in the areas of gene therapy and cardiovascular risk reduction.